![Regorafenib Catalog No.:M10913-10 5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl}-4-[(3R](https://cdn.shopify.com/s/files/1/0389/1897/9723/products/M10913_1621562681.gif?v=1621562683)
Pay in 4 interest-free payments of $18.75 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl}-4-[(3R
AMDINOCILLIN
under conditions in which the only other kinase tested that is significantly inhibited is MSK1 whose activity is reduced ~5-fold
InChiKey: UYARPHAXAJAZLU-KQYNXXCUSA-N
The oxocarbazate caused a time-dependent 17-fold drop in IC50 from 6
Regorafenib Catalog No.:M10913-10 5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl}-4-[(3RRegorafenib, also known as BAY 73 4506 ; is a n orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. Regorafenib demonstrated to increase the overall survival of patients with metastatic
US$ 1870.00
US$ 60000.00
US$ 1685.00
US$ 65.00
US$ 750.00
US$ 32.99
US$ 12500.00
US$ 45.00
US$ 180.00
US$ 290.00
US$ 105.00